Director: Paul C Langley

The company is under the direction of Dr Paul C Langley. Dr Langley trained as an economist and has been active in the area of health technology assessment and market access for the past 20 years. Dr Langley had advised all the leading pharmaceutical manufacturers on strategies for market access and on meeting evidentiary and analytical requirements for reimbursement applications. Dr Langley has undertaken consultancy assignments in the US, Canada, UK, Germany, Spain, Australia and New Zealand. Dr Langley has a significant number of publications. Fifty are currently cited on PubMed. Dr Langley has also published a number of monographs, with a particular focus on health economics and related activities over the drug life cycle.

Dr Langley has extensive experience in working with pharmacy and therapeutics committees in drug evaluation. He was the first author to publish guidelines for formulary evaluation of pharmaceuticals in the US (Foundation Health of California, 1996; Blue Cross and Blue Shield of Colorado and Nevada 1999) and was instrumental in developing the guidelines recommended by the Academy of Managed Care Pharmacy.

Dr  Langley received his undergraduate training in the UK and his post-graduate training in Canada, with a Ph.D. in Economics from Queen’s University. Following graduation, Dr Langley taught at universities in Canada, the United Kingdom, Australia and the United States. He moved to the US in 1994 (from La Trobe University, Melbourne where he had been Senior Lecturer in Economics and Department Head) as Associate Professor, College of Pharmacy in the Health Sciences Center. He focused on teaching and research at the postgraduate level within the Center for Pharmacoeconomics. In 1997 Dr Langley accepted a position as full Professor in the College of Pharmacy, University of Colorado in the Health Sciences Centre – again with responsibilities for developing programs in health technology assessment. He was recruited in August 1999 by the 3M Company in St Paul, MN as US and International Manager, Health Economics with the 3M Pharmaceuticals Division. At 3M he was responsible for developing and managing global research and marketing programs to support the development and market entry of 3M pharmaceutical products – in asthma, basal cell carcinoma, actinic keratosis, genital warts and genital herpes. Dr Langley was responsible for reimbursement submissions to national agencies (NICE in the UK, PBAC in Australia) to support product formulary listing and reimbursement. In 2000, Dr Langley was appointed full Professor (Adjunct) in the College of Pharmacy, University of Minnesota. He continues to hold this position as has taught in courses at the UofM in health technology assessment and reimbursement at the postgraduate level. Dr Langley left 3M Pharmaceuticals in August 2005 and re-established his consulting company, Maimon Research LLC.

Most recently, Dr Langley has edited a supplement to the Journal of Medical Economics (December 2015) on the status of modeled claims in pharmacoeconomics. The papers in the supplement focus on the credibility of cost and outcomes claims for the impact of products anbd devices in health systems. The papers in the supplement point out that few pharmacvoeconomic models meet the standards of normal science. They are best desribed as thought experiments or imaginary worlds. They have no scientific credibility because they do not generate testable predictions. Dr Langley proposes a new research agenda to focus on modeled claims that generate testable predictions.